Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol
First generation antipsychotics induce extrapyramidal motor symptoms (EPS), presumably through dopamine D2 receptor blockade at the dorsal striatum. This may also produce impairment of cognitive processes, such as procedural learning, that are dependent on this region. Haloperidol and, to a lesser extent, risperidone, are active in the dorsal striatum and may induce EPS and impairment of procedural learning. In contrast, the prototypical second-generation antipsychotic, clozapine, is less active in the dorsal striatum and does not induce EPS or impair procedural learning. Olanzapine is pharmacologically similar to clozapine and has a low incidence of EPS induction.
To assess the hypothesis that olanzapine would not have a deleterious effect on procedural learning.
Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine. They were administered the Tower of Toronto test at an unmedicated baseline and again following 6 weeks and 6 months of treatment.
Procedural learning, defined as the improvement observed between two blocks of five trials of the Tower of Toronto, was preserved after 6 weeks of all three treatments but showed a substantial decline after 6 months of treatment with haloperidol or risperidone.
These data are consistent with the differential activity of the three medications in dorsal striatum structures and suggest that the advantages of olanzapine over haloperidol and risperidone in relation to extrapyramidal syndromes may also generalize to procedural learning. The results also suggest that the procedural learning disadvantages of haloperidol and risperidone accrue slowly but are apparent after 6 months of treatment.
KeywordsSchizophrenia Procedural learning Dorsal striatum Olanzapine Risperidone Haloperidol
This work was supported by an investigator initiated grant from Eli Lilly and Company.
- Bedard MA, Scherer H, Stip E, Cohen H, Rodriguez JP, Richer F (2000) Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cognit 43:31–39Google Scholar
- Chouinard G, Jones B, Remington G, Bloom, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40PubMedGoogle Scholar
- Danion JM, Peretti S, Grange D, Bilik M, Imbs JL, Singer L (1992) Effects of chlorpromazine and lorazepam on explicit memory, repetition priming, and cognitive skill learning in healthy volunteers. Psychopharmacology 108:345–351Google Scholar
- Goldberg TE, Saint-Cyr JA, Weinberger DR (1990) Assessment of procedural learning and problem solving in schizophrenic patients by Tower of Hanoi type tasks. J Neuropsychiatr Clin Neurosci 2:165–173Google Scholar
- Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799–804Google Scholar
- Kay SR, Opler LA, Fiszbein A (1992) Positive and Negative Syndrome Scale (PANSS) manual. Multi-Health Systems Inc., North Tonawanda, N.Y.Google Scholar
- Kornetsky C, Humphries O (1957) Relationship between effects of a number of centrally acting drugs and personalty. AMA Arch Neurol Psychiatry 77:325–327Google Scholar
- Kornetsky C, Pettit M, Wynne R (1959) A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenia patients. J Ment Sci 105:190–198Google Scholar
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51–68PubMedGoogle Scholar
- Obeso JA, Rodriguez MC, DeLong MR (1997) Basal ganglia pathophysiology: a critical review. In: Obeso JA, DeLong MR, Ohye C, Marsden CD (eds) The basal ganglia and new surgical approaches for Parkinson's disease. Lippinicott-Raven, Philadelphia, pp 3–18Google Scholar
- Purdon SE, Mohr E, Ilivitsky V, Jones BD (1994) Huntington's disease: pathogenesis, diagnosis and treatment. J Psychiatr Neurosci 19:359–367Google Scholar
- Purdon SE, Malla A, LaBelle A, Lit W (2001a) Neuropsychological change in schizophrenia after 6 months of double blind treatment with quetiapine or haloperidol. J Psychiatr Neurosci 26:137–149Google Scholar
- Schwartz BL, Rosse RB, Veazay C, Deutsch SI (1996) Impaired motor skill learning in schizophrenia: implications for corticostriatal dysfunction. Biol Psychiatry 39:241–248Google Scholar
- Tandon R, Milner K, Jibson MD (1999) Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 60:21–28Google Scholar